

UPL Ltd.



Imhudundu

4th November 2020

| India Equit | y Institutional R | esearch II Result U | pdate – Q2FY21 | 4 th November, 2020 | Page 2 | | |
|--|-------------------|---------------------------------|--|--------------------------------|--------------------------------|--|--|
| UPL Ltd Strong quarter; EBITDA margin to improve with synergy benefits | | | | | | | |
| CMP INR 417 | Target INR 622 | Potential Upside 49 % | Market Cap (INR Mn) 3,19,043 |) Recommendation BUY | Sector Agrochemicals | | |

Result highlights

- UPL Ltd reported consolidated Revenue growth of 14.4% YoY (up 14.1% QoQ) to INR 89.4 bn.
- EBITDA for the quarter grew 15.2% YoY (down 9.0% QoQ) to INR 16.7 bn while EBITDA margin remained flat YoY at 18.6% (-474bps QoQ) in Q2FY21 (from 18.5% last year).
- Company reported Net Profit growth of 179% YoY (down 16.0% QoQ) to INR 4.6bn. Adjusted for exceptional items, Adjusted Net Profit grew 43.1% YoY (up 17.0% QoQ) to INR 6.7bn. Reported NPM for the quarter came in at 5.2% (+300bps YoY, -185bps QoQ) while Adjusted NPM stood at 7.5% (+151bps YoY, flat QoQ).
- Exceptional Items for the quarter mainly include cost related to restructuring, severance and litigation costs related to the Group's business in the Europe and Latin America.

| MARKET DATA | |
|---------------------|----------|
| Shares outs (Mn) | 765 |
| Equity Cap (INR Mn) | 225,940 |
| Mkt Cap (INR Mn) | 3,19,043 |
| 52 Wk H/L (INR) | 617/240 |
| Volume Avg (3m K) | 5,450 |
| Face Value (INR) | 2 |
| Bloomberg Code | UPLL IN |

| KEY FINANCIALS | | | | | | | | |
|----------------------|----------|----------|----------|----------|----------|--|--|--|
| Particulars (INR mn) | FY18 | FY19 | FY20 | FY21E | FY22E | | | |
| Revenues | 1,73,780 | 2,18,370 | 3,57,560 | 3,84,031 | 4,18,091 | | | |
| EBITDA | 35,050 | 38,130 | 67,730 | 82,567 | 94,071 | | | |
| Adj. PAT | 21,237 | 19,420 | 23,990 | 27,938 | 35,372 | | | |
| EPS Diluted (INR) | 41.6 | 38.0 | 31.3 | 36.4 | 46.1 | | | |
| EBITDA Margin (%) | 20.2% | 17.5% | 18.9% | 21.5% | 22.5% | | | |
| NPM (%) | 12.2% | 8.9% | 6.7% | 7.3% | 8.5% | | | |

Source: Company, KRChoksey Research

Strong performance in Q2FY21; management maintains guidance:

UPL's growth in Q2FY21 was largely led by volume growth of 19% YoY due to market share gains in key territories combined with favorable weather patterns in Brazil, US, Andean and parts of EU. Growth in volume was somewhat offset by prices declining -1.0% YoY and -4.0% YoY forex impact.


Geography wise, Latin America grew 12.4% YoY (47% of revenue) on the back of strong volume growth witnessed in Chile, Argentina and Paraguay and partially offset the adverse exchange impact. Europe grew 6.2% YoY (11% of revenue) due to benefit of integration; North America grew 8.7% YoY (9% of revenue) due to better weather conditions; India grew 17.9% YoY (16% of revenue) driven by herbicides in Rice and Soybeans supported by intensification of monsoons while RoW grew 27.2% YoY (17% of revenue) due to higher contribution from South East Asia with new product launches as well as better weather conditions in South Africa, Australia, New Zealand.

Forex movement affects GPS; cost savings holds up EBITDA margin:

Currency devaluation in Brazil and several countries in LATAM (e.g. Mexico), impacted Gross Profit Margin in quarter. Company reported GPM of 40% in Q2FY21 against 42% in Q2FY20. Though, through cost savings in overheads & employee cost, company was able to maintain EBITDA margin at Q2FY20 level, at around 18.6% (+14bps YoY, -474bps QoQ).

Update on Debt:


As of 30th September 2020, UPL's net debt was INR 238.4 bn, higher by INR 17.8 bn compared to 31st March 2020 mainly due to an increase in working capital of INR 29.2 bn, in line with the seasonality of the business. Company to reduce net debt in H2FY21 and maintain an investment grade credit rating.



ANAI YST Parvati Rai, head-research@krchoksey.com, +91-22-66965413

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com

SHARE PRICE PERFORMANCE



MARKET INFO

| SENSEX | 40,261 |
|--------|--------|
| NIFTY | 11,811 |

| Particulars | Sep-20 (%) | Jun-20 (%) | Mar-20 (%) |
|-------------|------------|------------|------------|
| Promoters | 27.9 | 27.9 | 27.89 |
| FIIs | 37.2 | 40.6 | 43.50 |
| DIIs | 16.2 | 13.4 | 11.45 |
| Others | 18.7 | 18.4 | 17.16 |
| Total | 100 | 100 | 100 |

India Equity Institutional Research II

Result Update – Q2FY21

UPL Ltd

Concall Highlights:

(i) FY2021 Outlook: Company has maintained its guidance of 6-8% growth in revenue and 10-12% in EBITDA. The growth will be driven by a focus on differentiated solutions as well as new product launches (ii) Price increases in local currencies and cost savings will support margins (iii) Company's Net debt has increased marginally by ~INR 17bn QoQ in Q2FY21 due to higher working capital requirements (iv) UPL has guided for net debt reduction of USD700-750mn YoY in 2HFY21. Company intends to keep Net debt/EBITDA at 2.0x by FY21 as against 2.9x currently, with net debt reduction 2HFY21 (v) Management has highlighted that the company is outperforming its guidance for cost as well as revenue synergy by achieving revenue synergy of USD 299 mn in just 5 quarter of integration (vs target of USD 350mn in 3 years) and cost synergy of USD 153 mn currently (vs target of USD 200mn in 2 years).

Valuation & Outlook:

Change in geography mix towards low margin regions, lower prices & currency devaluation in Brazil and several countries in LATAM (e.g. Mexico), impacted Gross Profit Margin of UPL in Q2FY21, though company was able to maintain EBITDA margin with cost savings in overheads & employee costs. Management expects EBITDA margin improvement in full year numbers & going forward EBITDA margin to be in the range of 23-25% in next few years. UPL today is the number one bio solutions company and the largest supplier of organic portfolio of products in the world. The value of the company's pipeline is valued currently at USD 2.0 bn to USD 2.5 bn of peak sales, reaching maturity in the next five to eight years. Moreover, the company has highlighted that they expect USD 5.0 bn of additional market value from products becoming off-patent in the next five years, and that being backwards integrated with scale renders UPL to take a large share of this market. Since our last earnings update on the stock (at INR 487/share), the stock has corrected 14.4%. At a CMP of INR 417, UPL is trading at a valuation of 11.5/9.0x FY21/22E EPS. We continue to apply PE multiple of 13.5x on our FY22E EPS of INR 46.1/share and maintain our Target Price of INR 622/share with a potential upside of 49%. Accordingly, we maintain our "BUY" rating on the stock. The potential downside to our recommendation in near term arises from the resignation of company's auditors at UPL Corp & allegations regarding director numerations.

| Sales Growth (%) | Q2FY20 | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 |
|------------------|--------|--------|--------|--------|--------|
| Volume | 15.0 | 10.0 | 29.0 | 0.0% | 19% |
| Price | -1.0 | -1.0 | -2.0 | -1.0% | -1.0% |
| Exchange | -3.0 | -2.0 | -2.0 | 0.0% | -4.0% |

| Segmental Revenue | Q2FY20 | Q3FY20 | Q4FY20 | Q1FY21 | Q2FY21 | QoQ | ΥοΥ |
|-------------------|--------|--------|--------|--------|--------|--------|-------|
| North America | 6.2 | 12.9 | 25.4 | 10.3 | 7.7 | -24.7% | 24.7% |
| India | 12.0 | 7.5 | 7.0 | 15.1 | 14.1 | -6.8% | 17.4% |
| Europe | 9.1 | 7.7 | 20.4 | 17.0 | 10.2 | -40.0% | 12.3% |
| LATAM | 37.7 | 42.0 | 34.2 | 20.2 | 42.3 | 110.1% | 12.3% |
| ROW | 13.3 | 18.8 | 24.4 | 15.8 | 15.0 | -4.8% | 13.0% |
| Total | 78.3 | 88.9 | 111.4 | 78.3 | 89.4 | 14.1% | 14.2% |

KRChoksey Institutional

India Equity Institutional Research

Result Update – Q2FY21

ll 4th November, 2020

Page 4

UPL Ltd

Financials:

Income Statement:

| Particulars (INR mn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|----------------------------|----------|----------|----------|----------|----------|
| Revenues | 1,73,780 | 2,18,370 | 3,57,560 | 3,84,031 | 4,18,091 |
| Raw Material Cost | 81,120 | 1,09,040 | 1,87,430 | 1,84,335 | 2,04,865 |
| Gross Profit | 92,660 | 1,09,330 | 1,70,130 | 1,99,696 | 2,13,227 |
| Gross Margin (%) | 53.3% | 50.1% | 47.6% | 52.0% | 51.0% |
| Employee Costs | 17,130 | 20,950 | 33,910 | 40,323 | 43,900 |
| Other Direct Expenses | 40,480 | 47,260 | 65,180 | 76,806 | 75,256 |
| Total Operating Expenses | 57,610 | 68,210 | 99,090 | 1,17,130 | 1,19,156 |
| EBITDA | 35,050 | 38,130 | 67,730 | 82,567 | 94,071 |
| EBITDA Margin (%) | 20.2% | 17.5% | 18.9% | 21.5% | 22.5% |
| Depreciation | 6,750 | 8,800 | 20,120 | 24,657 | 23,695 |
| Other income | 4,140 | 2,400 | 1,040 | 1,920 | 2,090 |
| EBIT | 28,300 | 29,330 | 47,610 | 57,910 | 70,375 |
| EBIT Margin (%) | 16.28% | 13.43% | 13.32% | 15.08% | 16.83% |
| Finance Cost | 7,830 | 9,630 | 14,810 | 20,068 | 21,255 |
| Exceptional Items | -630 | -7,500 | -9,540 | -2,360 | 0 |
| Profit before Tax (PBT) | 23,980 | 17,590 | 27,610 | 37,402 | 51,210 |
| Tax Expense | 2,363 | 1,980 | 5,860 | 8,041 | 11,522 |
| Profit after Tax (PAT) | 21,617 | 15,610 | 21,750 | 29,360 | 39,688 |
| Share of P/L of associates | -930 | 140 | 30 | 35 | 50 |
| Minority Interest | 80 | 840 | 4,020 | 3,817 | 4,366 |
| Reported PAT | 20,607 | 14,910 | 17,760 | 25,578 | 35,372 |
| PAT Margin (%) | 11.9% | 6.8% | 5.0% | 6.7% | 8.5% |
| Adj. PAT | 21,237 | 19,420 | 23,990 | 27,938 | 35,372 |
| Adj PAT Margin (%) | 12.2% | 8.9% | 6.7% | 7.3% | 8.5% |
| Basic EPS | 40.4 | 29.2 | 23.2 | 33.4 | 46.1 |
| Adj Diluted EPS | 41.6 | 38.0 | 31.3 | 36.4 | 46.1 |

Source: Company, KRChokseyResearch

Cashflow Statement:

| Particulars (INR mn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|--|---------|-----------|---------|---------|----------|
| Net Cash generated from/(used in) operating activities | 28,390 | 23,560 | 87,390 | 61,931 | 88,764 |
| Net Cash Used In Investing Activities | -20,930 | -3,09,200 | -26,430 | -13,150 | -12,230 |
| Net Cash Used in Financing Activities | -8,010 | 2,88,940 | -21,750 | -27,449 | -49,636 |
| Net Inc/(Dec) in Cash & Cash Eq. | -550 | 3,300 | 39,210 | 21,332 | 26,899 |
| Cash & Cash Equivalents at the beg | 28,800 | 28,590 | 28,260 | 67,240 | 88,572 |
| Cash & Cash Equivalents at the end | 28,250 | 31,890 | 67,470 | 88,572 | 1,15,470 |
| Adjustments | 690 | -3,380 | 50 | 280 | 280 |
| Cash & Bank Balance | 28,940 | 28,510 | 67,520 | 88,852 | 1,15,750 |

Source: Company, KRChoksey Research

ANALYST

Parvati Rai, head-research@krchoksey.com, +91-22-66965413

KRChoksey Research is also available on Bloomberg KRCS<GO> Thomson Reuters, Factset and Capital IQ Phone: +91-22-6696 5555, Fax: +91-22-6691 9576 www.krchoksey.com

| India Equity Institutional Research II | Result Update – Q2FY21 | ll 4 th November, 2020 | Page |
|--|------------------------|-----------------------------------|------|
| | | | |

UPL Ltd

| Balance Sheet | | | | | |
|---|----------|----------|----------|----------|----------|
| Particulars (INR mn) | FY18 | FY19 | FY20 | FY21E | FY22E |
| Share capital | 1,020 | 1,020 | 1,530 | 1,530 | 1,530 |
| Reserves and surplus | 90,670 | 1,46,130 | 1,61,430 | 1,79,628 | 2,07,620 |
| Issue of perpetual bond | 0 | 0 | 29,860 | 29,860 | 29,860 |
| Minority Interest | 190 | 34,540 | 33,120 | 36,937 | 41,303 |
| Total Equity | 91,880 | 1,81,690 | 2,25,940 | 2,47,955 | 2,80,312 |
| Long-term borrowings | 58,730 | 2,63,830 | 2,73,710 | 2,73,710 | 2,53,710 |
| Deferred tax liabilities (Net) | 880 | 21,970 | 27,770 | 27,770 | 27,770 |
| Other long term liabilities | 2,320 | 1,360 | 6,310 | 6,310 | 6,310 |
| Long-term provisions | 200 | 200 | 240 | 240 | 240 |
| Total Non-current liabilities | 62,130 | 2,87,360 | 3,08,030 | 3,08,030 | 2,88,030 |
| Short-term borrowings | 6,340 | 24,780 | 12,980 | 12,980 | 11,980 |
| Trade payables | 56,750 | 98,470 | 1,02,330 | 1,15,735 | 1,37,455 |
| Other current liabilities | 12,420 | 30,240 | 40,449 | 31,564 | 34,364 |
| Short-term provisions | 910 | 9,120 | 11,101 | 11,923 | 12,980 |
| Total Current liabilities | 76,420 | 1,62,610 | 1,66,860 | 1,72,203 | 1,96,779 |
| Total Equity and liabilities | 2,30,430 | 6,31,660 | 7,00,830 | 7,28,187 | 7,65,121 |
| Assets | | | | | |
| Net Block | 40,050 | 1,55,220 | 1,64,380 | 1,52,873 | 1,41,408 |
| Capital work in progress | 10,900 | 11,660 | 10,590 | 10,590 | 10,590 |
| Intangible asset under development | 2,290 | 6,890 | 10,140 | 10,140 | 10,140 |
| Goodwill on consolidation | 4,320 | 1,66,270 | 1,82,410 | 1,82,410 | 1,82,410 |
| Investments accounted using equity method | 3,860 | 4,080 | 3,600 | 3,600 | 3,600 |
| Non-current investments | 6,480 | 2,980 | 1,980 | 1,980 | 1,980 |
| Deferred tax assets | 5,290 | 7,310 | 16,550 | 16,550 | 16,550 |
| Long-term loans and advances | 1,510 | 1,560 | 1,570 | 1,570 | 1,570 |
| Other non-current assets | 5,480 | 8,430 | 15,300 | 15,300 | 15,300 |
| Trade receivables | 10 | 40 | 1,900 | 1,900 | 1,900 |
| Total Non-current assets | 80,190 | 3,64,440 | 4,08,420 | 3,96,913 | 3,85,448 |
| Current Investments | 0 | 20 | 0 | 0 | 0 |
| Inventories | 45,380 | 91,330 | 78,500 | 89,432 | 97,364 |
| Trade receivables | 60,560 | 1,16,790 | 1,18,670 | 1,26,257 | 1,37,455 |
| Cash and bank balances | 28,940 | 28,510 | 67,520 | 88,852 | 1,15,750 |
| Short-term loans and advances | 1,470 | 510 | 400 | 430 | 468 |
| Other current assets | 13,890 | 30,060 | 27,320 | 26,304 | 28,636 |
| Total current assets | 1,50,240 | 2,67,220 | 2,92,410 | 3,31,274 | 3,79,673 |
| Total Assets | 2,30,430 | 6,31,660 | 7,00,830 | 7,28,187 | 7,65,121 |

Source: Company, KRChoksey Research

| Key Ratio | FY18 | FY19 | FY20 | FY21E | FY22E |
|----------------------------|-------|-------|-------|-------|-------|
| EBITDA Margin | 20.2% | 17.5% | 18.9% | 21.5% | 22.5% |
| Tax rate (%) | 9.7% | 11.3% | 21.2% | 21.5% | 22.5% |
| Adj. Net Profit Margin (%) | 12.2% | 8.9% | 6.7% | 7.3% | 8.5% |
| RoE (%) | 22.4% | 8.2% | 7.9% | 10.3% | 12.6% |
| RoCE (%) | 18.0% | 6.2% | 9.3% | 10.8% | 12.9% |
| Current Ratio (x) | 2.0 | 1.6 | 1.8 | 1.9 | 1.9 |
| Adj. EPS (INR per share) | 41.6 | 38.0 | 31.3 | 36.4 | 46.1 |

Source: Company, KRChokseyResearch

5

India Equity Institutional Research

Result Update – Q2FY21

ll 4th November, 2020

Page 6

| | | | - |
|---|----------------|-----|------------------|
| | | 1 1 | _ |
| | $\mathbf{\nu}$ | т. | \boldsymbol{n} |
| U | ΡL | Lt | u |

| UPL Ltd | | | Rating Legend | | |
|-----------|-----------|----------|----------------|------------|--------------------|
| Date | CMP (INR) | TP (INR) | Recommendation | Our Rating | Upside |
| 03-Nov-20 | 417 | 622 | BUY | | |
| 12-Aug-20 | 487 | 622 | BUY | Buy | More than 15% |
| 05-Jun-20 | 419 | 614 | BUY | Duy | more than 15% |
| 26-May-20 | 367 | 614 | BUY | | |
| 10-Feb-20 | 543 | 667 | BUY | Accumulate | 5% – 15% |
| 11-Nov-19 | 555 | 667 | BUY | Accumulate | 2% - 12% |
| 5-Aug-19 | 541 | 761 | BUY | Hold | o – 5% |
| 23-May-19 | 1011 | 1142 | ACCUMULATE | noia | |
| 02-Aug-18 | 636 | 763 | BUY | Deduce | 5 ⁹ / 0 |
| 02-May-18 | 732 | 998 | BUY | Reduce | -5% – 0 |
| 29-Jan-18 | 789 | 1030 | BUY | Sell | Less than – 5% |

ANALYST CERTIFICATION:

I, Parvati Rai (MBA-Finance, M.com), Head Research, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered Research Entity vides SEBI Registration No. INHooooo1295 under SEBI (Research Analyst) Regulations, 2014.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

KRCSSPL prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed he

Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, Parvati Rai (MBA-Finance, M.com), Head Research do not serve as an officer, director or employee of the companies mentioned in the report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com Visit us at www.krchoksey.com KRchoksey Shares and Securities PVL. Ltd Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001. Phone: +91-22-6633 S000; Fax: +91-22-6633 8060. Corporate Office: ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: +91-22-6696 5555; Fax: +91-22-6691 9576.